ArticleInternational journal of endocrinology2012
Mechanisms of action of topical corticosteroids in psoriasis.
Article in International journal of endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 230 citations in OpenAlex.
- Article
- A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026Review
- Topical oleic acid reduces nociception and inflammation in a UVB radiation-induced sunburn model in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Substance-Based Medical Device in Wound Care: Bridging Regulatory Clarity and Therapeutic Innovation.Polymers · 2025Review
- Comparison of the Effectiveness Differences between Western and Chinese Medicinal Ointments against Eczema.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Synergistic Combinations of Native Australian Plants For Skin Inflammation and Wound Healing.Biomedicines · 2025Article
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Exosomes and Exosome-Mimetics for Atopic Dermatitis Therapy.Tissue engineering and regenerative medicine · 2025Review
- Biochanin A Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice by Modulating the NF-κB and MAPK Signaling Pathways.Inflammation · 2025Article
- Poly(lactic Acid) Fibers for Sustained Drug Delivery: Insights into Release Profiles and Cellular Interactions.Materials (Basel, Switzerland) · 2025Article
- Insights into Liposomal and Gel-Based Formulations for Dermatological Treatments.Gels (Basel, Switzerland) · 2025Review
- Review
- Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need.Drugs & aging · 2025Review
- Transcription factors in the development and treatment of immune disorders.Transcription · 2025Review
- Utilization and prescription patterns of topical steroids: a study at dessie comprehensive specialized hospital, Ethiopia.Archives of dermatological research · 2025Article
- Anti-Psoriatic Efficacies of Psorogrit and Divya-Taila, in Murine Models of Imiquimod and TPA-Induced Psoriasis-Like Inflammation are Driven by Modulation in IL-17RA/IL-23 and IL-8/TNF-α Signaling Axes.Journal of inflammation research · 2025Article
- Radon exposure delays the development of skin lesions in a mouse model of psoriasis.Frontiers in immunology · 2025Article
- Emulgel-Based Formulations of Clobetasol Propionate: Formulation Development, Characterization, and Pharmacological Evaluation.Pharmaceutical nanotechnology · 2025Review
- Complicated iatrogenic Cushing's syndrome induced by topical clobetasol propionate in a child with psoriasis: a case report and review of the literature.Journal of medical case reports · 2024Review
- Intradermal Injection of a Thermoresponsive Polymeric Dexamethasone Prodrug (ProGel-Dex) Ameliorate Dermatitis in an Imiquimod (IMQ)-Induced Psoriasis-like Mouse Model.Molecular pharmaceutics · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a lifelong, chronic, and immune-mediated systemic disease, which affects approximately 1-3% of the Caucasian population. The different presentations of psoriasis require different approaches to treatment and appropriate prescriptions according to disease severity. The use of topical therapy remains a key component of the management of almost all psoriasis patients, and while mild disease is commonly treated only with topical agents, the use of topical therapy as adjuvant therapy in moderate-to-severe disease may also be helpful. This paper focuses on the cutaneous mechanisms of action of corticosteroids and on the currently available topical treatments, taking into account adverse effects, bioavailability, new combination treatments, and strategies to improve the safety of corticosteroids. It is established that the treatment choice should be tailored to match the individual patient's needs and his/her expectations, prescribing to each patient the most suitable vehicle.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.